8.5 USD
+0.01 (+0.12%)
Last: Sep 25, 2023, 08:00 PM
Taking everything into account, LMNL scores 2 out of 10 in our fundamental rating. LMNL was compared to 524 industry peers in the Biotechnology industry. LMNL has a bad profitability rating. Also its financial health evaluation is rather negative. LMNL is valued expensive and it does not seem to be growing.
1. Profitability
1.1 Basic Checks
- LMNL had positive earnings in the past year.
- In the past year LMNL has reported a negative cash flow from operations.
1.2 Ratios
- The Return On Assets of LMNL (1.46%) is better than 93.73% of its industry peers.
- LMNL has a Return On Equity of 2.16%. This is amongst the best in the industry. LMNL outperforms 93.73% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 1.46% | ||
| ROE | 2.16% | ||
| ROIC | N/A |
ROA(3y)-29.63%
ROA(5y)-80.67%
ROE(3y)-159.64%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
- LMNL has a Profit Margin of 94.11%. This is amongst the best in the industry. LMNL outperforms 99.67% of its industry peers.
- LMNL does not have Operating Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | 94.11% | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
- LMNL does not have a ROIC to compare to the WACC, probably because it is not profitable.
- Compared to 1 year ago, LMNL has about the same amount of shares outstanding.
- The debt/assets ratio for LMNL has been reduced compared to a year ago.
2.2 Solvency
- LMNL has an Altman-Z score of -45.25. This is a bad value and indicates that LMNL is not financially healthy and even has some risk of bankruptcy.
- Looking at the Altman-Z score, with a value of -45.25, LMNL is doing worse than 95.71% of the companies in the same industry.
- LMNL has a Debt/Equity ratio of 0.02. This is a healthy value indicating a solid balance between debt and equity.
- With a Debt to Equity ratio value of 0.02, LMNL perfoms like the industry average, outperforming 41.09% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.02 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -45.25 |
ROIC/WACCN/A
WACC7.87%
2.3 Liquidity
- LMNL has a Current Ratio of 2.78. This indicates that LMNL is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Current ratio, with a value of 2.78, LMNL is doing worse than 74.75% of the companies in the same industry.
- LMNL has a Quick Ratio of 2.78. This indicates that LMNL is financially healthy and has no problem in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 2.78, LMNL is doing worse than 72.94% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.78 | ||
| Quick Ratio | 2.78 |
3. Growth
3.1 Past
- The earnings per share for LMNL have decreased strongly by -99.10% in the last year.
- Looking at the last year, LMNL shows a very negative growth in Revenue. The Revenue has decreased by -12.92% in the last year.
- The Revenue for LMNL have been decreasing by -59.99% on average. This is quite bad
EPS 1Y (TTM)-99.1%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-53.93%
Revenue 1Y (TTM)-12.92%
Revenue growth 3Y-56.58%
Revenue growth 5Y-59.99%
Sales Q2Q%-28.66%
3.2 Future
- Based on estimates for the next years, LMNL will show a very negative growth in Earnings Per Share. The EPS will decrease by -230.98% on average per year.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-907.27%
EPS Next 2Y-230.98%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 77.27 indicates a quite expensive valuation of LMNL.
- Based on the Price/Earnings ratio, LMNL is valued cheaply inside the industry as 93.89% of the companies are valued more expensively.
- The average S&P500 Price/Earnings ratio is at 28.32. LMNL is valued rather expensively when compared to this.
- The Forward Price/Earnings Ratio is negative for LMNL. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 77.27 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
- A cheap valuation may be justified as LMNL's earnings are expected to decrease with -230.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-230.98%
EPS Next 3YN/A
5. Dividend
5.1 Amount
- LMNL does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
LIMINAL BIOSCIENCES INC / LMNL FAQ
What is the ChartMill fundamental rating of LIMINAL BIOSCIENCES INC (LMNL) stock?
ChartMill assigns a fundamental rating of 2 / 10 to LMNL.
What is the valuation status for LMNL stock?
ChartMill assigns a valuation rating of 1 / 10 to LIMINAL BIOSCIENCES INC (LMNL). This can be considered as Overvalued.
Can you provide the profitability details for LIMINAL BIOSCIENCES INC?
LIMINAL BIOSCIENCES INC (LMNL) has a profitability rating of 3 / 10.
Can you provide the financial health for LMNL stock?
The financial health rating of LIMINAL BIOSCIENCES INC (LMNL) is 3 / 10.
What is the earnings growth outlook for LIMINAL BIOSCIENCES INC?
The Earnings per Share (EPS) of LIMINAL BIOSCIENCES INC (LMNL) is expected to decline by -907.27% in the next year.